Description
Determination of the presence and variants of the BCR/ABL – t(9;22) chimeric gene is a crucial diagnostic procedure for chronic myeloid leukemia, reliably confirming the diagnosis in 98% of patients, as well as for acute lymphoblastic leukemia in 10-15% of cases.
Period of execution
Within 10 days. The specified time does not include the day of biomaterial collection
Biomaterial type